跳至主要内容
临床试验/NCT00381966
NCT00381966已完成不适用

A Pilot Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2006年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
5
试验地点
1
主要终点
Positioning Effectiveness as Determined by Confirmatory Measurements of Robotic Movements

研究概览

简要总结

This is a study that will try see if a device can help to better guide the needle that places prostate cancer treatment.

详细描述

Section 1- Background:

Adenocarcinoma of the prostate will affect over 220,900 U.S. males this year, making it the most prevalent cancer in the nation.1 Prostate specific antigen (PSA) is a very useful tumor marker in early detection of this malignancy, as well as a reliable marker for control after definitive therapy with either surgery or irradiation. Widespread use of prostate-specific antigen (PSA) screening has resulted in approximately 45% of patients being detected with early stage disease. For this group of patients, brachytherapy or implantation of radioactive sources into the prostate is a treatment option that has risen dramatically in use over the last several years due to its effectiveness and convenience.

The use of brachytherapy or implantation of radioactive sources into the prostate for adenocarcinoma has advantages over external beam radiation in that a very high dose can be delivered to the tumor while limiting the doses to the surrounding normal tissue (i.e., bowel and bladder). It is well established that outcomes after treatment with brachytherapy are critically related to the technical quality of source placement within the gland. A spatially desirable placement of the radioactive sources with achievement of optimum dose distributions within the prostate is key to the success of brachytherapy with regard to both killing tumor as well as minimizing toxicity.

The development of transrectal ultrasound (TRUS) of the prostate, with the ability to map the prostate in several planes, as well as the associated development of trans-perineal implantation of the prostate, has allowed the development of the modern prostate implantation method. Ultrasound images are taken before or during the implant procedure, and a source distribution plan is developed that optimizes dose to the prostatic tissues while sparing the urethra and rectum. Needles are placed into the prostate via a transperineal template, and the sources are placed into the prostate according to the source distribution plan.

Currently, the template utilized for needle guidance is limited to 0.5 centimeter x-axis and y-axis grid spacing, limiting the ability of the needle positions to conform to the shape of the prostate, which is spherical (Fig 1). The most commonly utilized method of dosimetric planning involves placing needles around the periphery of the prostate capsule, in order to best cover potential microscopic extracapsular extension as well as to avoid the dose sensitive urethra which runs through the center. The grid arrangement of the current template limits the ability of these needle positions to best approximate the external contour of the prostate (Fig 2). Also, placement of sources in the most posterior row adjacent to rectum is critical. Sources too close to rectum may cause increased risk of rectal bleeding, whereas source too far from the capsule may result in risk of underdosing disease in that area. Greater freedom in needle positioning would allow for more optimum placement of sources.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •Inclusion criteria are unchanged from our standard criteria for brachytherapy eligibility:
  • •Histologically confirmed, locally confined adenocarcinoma of the prostate
  • •Clinical stages T1b - T2b
  • •PSA of less than 20 ng/mL
  • •Combined Gleason score 7 or less, with no individual Gleason score of 5
  • •The patient has decided to undergo brachytherapy at the Johns Hopkins Hospital as treatment choice for his prostate cancer.
  • •Karnofsky Performance Status (KPS) > 70
  • •Prostate volume by TRUS < 50 cc
  • •International Prostate symptom score (IPSS) must be 18 or less
  • •Signed study-specific consent form prior to registration

排除标准

  • •Stage T1a, or T3 or greater disease.
  • •Clinical or Pathological Lymph node involvement (N1).
  • •Evidence of distant metastases (M1).
  • •Radical surgery for carcinoma of the prostate.
  • •Previous Chemotherapy or pelvic radiation therapy
  • •Previous transurethral resection of the prostate (TURP)
  • •Significant obstructive symptoms (IPSS greater than 18)
  • •Hip prosthesis.
  • •Anatomic or medical condition (such as prior abdominal-perineal resection or anal stricture) which would preclude the use of TRUS

研究组 & 干预措施

Robotic placement device

Experimental

The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.

干预措施: robotic placement device (Device)

结局指标

主要结局

Positioning Effectiveness as Determined by Confirmatory Measurements of Robotic Movements

时间窗: at time of intervention

Confirmatory measurements of robotic movements was assessed using infrared tracking to calculate mean error in millimeters.

Utility of the Needle Position Device: Number of Adjustments Possible Out of Adjustments Attempted

时间窗: at time of intervention

Utility was demonstrated in terms of fine adjustments (≤ 2 mm) and adjustments \>2mm in needle positioning, being possible when tissue deflection was encountered.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验